Inventiva News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

25.05.23	Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China (GlobeNewswire)
25.05.23	Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 25 May 2023 (GlobeNewswire)
16.05.23	Inventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update (GlobeNewswire)
04.05.23	Statement of total voting rights and shares forming the company’s share capital as of April 17, 2023 (GlobeNewswire)
04.05.23	Combined General Meeting of May 25, 2023. Availability of the preparatory documents (GlobeNewswire)
30.03.23	Inventiva announces filing of its 2022 Universal Registration Document and 2022 Annual Report on Form 20-F (GlobeNewswire)
29.03.23	Inventiva reports its 2022 full-year results (GlobeNewswire)
23.03.23	Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results (GlobeNewswire)
14.02.23	Inventiva reports preliminary financial results for Full-Year 2022¹ (GlobeNewswire)
21.11.22	Inventiva announces a new Director of the Board of Directors (GlobeNewswire)
10.11.22	Inventiva reports 2022 Third Quarter Financial Information¹ (GlobeNewswire)
31.10.22	Inventiva provides an update on the development of cedirogant by AbbVie (GlobeNewswire)
21.10.22	Inventiva announces a scientific presentation at the AASLD The Liver Meeting® 2022 (GlobeNewswire)
22.09.22	Inventiva reports its 2022 first-half financial results and provides a corporate update (GlobeNewswire)
21.09.22	Inventiva and Sino Biopharm announce licensing and collaboration agreement to develop and commercialize lanifibranor in Greater China (GlobeNewswire)
07.09.22	Inventiva announces the schedule of publication and presentation of its 2022 Half-Year Financial Results (GlobeNewswire)
28.07.22	Inventiva Reports 2022 First-Half Financial Information¹ (GlobeNewswire)
07.07.22	Inventiva announces the screening of the first patient in LEGEND, a Phase IIa combination trial with lanifibranor and empagliflozin in patients with NASH and T2D (GlobeNewswire)
04.07.22	Update on Inventiva's cash position and on the finance documentation with the European Investment Bank (GlobeNewswire)
16.06.22	Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022 (GlobeNewswire)
09.06.22	Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022 (GlobeNewswire)
07.06.22	Inventiva joins the Euronext Tech Leaders segment (GlobeNewswire)
03.06.22	Inventiva announces the presentation of a scientific abstract at the 82nd Scientific Sessions of the American Diabetes Association (GlobeNewswire)
23.05.22	Inventiva announces participation at several investors conferences in May and June 2022 (GlobeNewswire)
19.05.22	Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 19 May 2022 (GlobeNewswire)
16.05.22	Inventiva reports 2022 First Quarter Financial Information and provides clinical development update (GlobeNewswire)
16.05.22	Inventiva secures a €50 million credit facility from the European Investment Bank (GlobeNewswire)
28.04.22	Statement of total voting rights and shares forming the company’s share capital as of April 11, 2022 (GlobeNewswire)
28.04.22	Combined General Meeting of May 19, 2022 - Availability of the preparatory documents (GlobeNewswire)
07.04.22	Inventiva announces the presentation of a scientific abstract at the next International Conference on Fatty Liver (GlobeNewswire)
08.03.22	Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA (GlobeNewswire)
07.03.22	Inventiva publie ses résultats annuels 2021 : Avancées majeures avec lanifibranor dans la NASH et cedirogant dans le psoriasis (GlobeNewswire)
01.03.22	Inventiva announces participation at several conferences in March 2022 (GlobeNewswire)
28.02.22	Inventiva announces the schedule of publication and presentation of its 2021 Full-Year Financial Results (GlobeNewswire)
14.02.22	Inventiva reports cash position and revenues for Full-Year 2021 (GlobeNewswire)
31.01.22	Inventiva receives a €4 million milestone payment from AbbVie for cedirogant Phase IIb initiation (GlobeNewswire)
20.01.22	Inventiva announces participation at several conferences in January and February 2022 (GlobeNewswire)
16.12.21	Inventiva to present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
06.12.21	Inventiva announces positive results of clinical thorough QT study conducted with lanifibranor (GlobeNewswire)
10.11.21	Inventiva reports 2021 Third Quarter Financial Information (GlobeNewswire)
03.11.21	Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021 (GlobeNewswire)
29.10.21	Inventiva announces participation at several conferences in November 2021 (GlobeNewswire)
27.10.21	Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes (GlobeNewswire)
20.10.21	The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH (GlobeNewswire)
18.10.21	Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting™ 2021 (GlobeNewswire)
28.09.21	Inventiva announces participation at several investor conferences in October 2021 (GlobeNewswire)
23.09.21	Inventiva completes sale of $30 million through its ATM program to existing and new specialized institutional investors (GlobeNewswire)
21.09.21	Inventiva announces FDA decision that Fast Track designation granted to lanifibranor in NASH encompasses the treatment of NASH with compensated cirrhosis (GlobeNewswire)
20.09.21	Inventiva reports 2021 first half financial results and provides a corporate update (GlobeNewswire)
18.09.21	Ausblick: Inventiva gewährt Anlegern Blick in die Bücher (finanzen.net)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Inventiva SA act ord

Aktien Top/Flop

Meistgelesene Nachrichten